about
The genome of the blood fluke Schistosoma mansoniGenomic-scale prioritization of drug targets: the TDR Targets databasePersonalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistanceStandard conformations for the canonical structures of immunoglobulinsHow many drug targets are there?ChEMBL: a large-scale bioactivity database for drug discoveryDistinctive Behaviors of Druggable Proteins in Cellular NetworksSCOPEC: a database of protein catalytic domains.Combining multiple structure and sequence alignments to improve sequence detection and alignment: application to the SH2 domains of Janus kinases.Sequence, structure and energetic determinants of phosphopeptide selectivity of SH2 domains.Effective function annotation through catalytic residue conservation.Collation and data-mining of literature bioactivity data for drug discovery.Minimum information about a bioactive entity (MIABE).Combinatorial drug therapy for cancer in the post-genomic era.Defective acute inflammation in Crohn's disease: a clinical investigation.Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology.Therapeutic opportunities within the DNA damage response.canSAR: updated cancer research and drug discovery knowledgebase.JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.canSAR: an updated cancer research and drug discovery knowledgebase.A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma.Personalized medicine: patient-predictive panel power.canSAR: an integrated cancer public translational research and drug discovery resourceA HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma.Blocking the survival of the nastiest by HSP90 inhibitionLigand efficiency indices for an effective mapping of chemico-biological space: the concept of an atlas-like representation.Drugging cancer genomes.The complement of enzymatic sets in different species.Unpicking the combination lock for mutant BRAF and RAS melanomas.New open drug activity data at EBIThe Molecular Basis of Predicting DruggabilityObjective assessment of cancer genes for drug discoveryProtein Structure PredictionThe kinase polypharmacology landscape of clinical PARP inhibitorsPublic resources for chemical probes: the journey so far and the road aheadDifferences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant CancersTransforming cancer drug discovery with Big Data and AI
P50
Q22122228-2CA8DF3D-A12A-4649-9C1D-07FBF7A510C4Q24635333-57D4F7B1-6E62-41C1-B732-C05687045742Q26866517-4CEC98C4-18BC-4C9E-BBC1-0B0CDE281B23Q28254522-04306CE0-3B9F-46B4-B93E-4387C0F3C2ABQ28276660-2B2AF2BA-1472-44D0-B6BF-49626A6842B2Q28315179-11F8EF41-A911-4477-B934-E8D217FE6516Q28551715-A7EBB0CB-6568-4297-B6C3-8BDD0492B0A1Q30342317-8632EB6D-5E26-4860-A06E-9916D840C019Q30667293-916BDAFC-ABF0-44BD-9536-C37E27DC3E45Q33195307-A438CB9F-67F6-40B8-91E9-F7C7087A1398Q33901767-D64E68D0-22B0-4D10-9F26-CE342A769F2CQ34026765-15E99A43-53F2-4B6E-A252-0903BB3EF865Q34212022-51F29A0F-3D55-4E6F-BBE1-EA13B2D77F20Q34287101-6E2CD55C-AA5C-47EC-B8A8-C3A16E581D38Q34497865-9AE5349A-B1BA-4E70-88C9-E761DB8E785BQ38117994-5B619F5A-E8EE-4229-ADCC-8F80FC5177FBQ38364665-FF8E886C-0012-43F7-9929-A4A72C8E4A69Q38488438-5F5DE7D3-49F6-4316-A899-61A181116878Q38688601-D9F4A389-F62F-4D06-A5C3-6701C1B0F4D5Q38811457-1E6FCCA5-5F64-444F-9996-D8D33C4DF891Q39167249-3753CE9E-8339-4EE2-8FE6-D74CF732BC6AQ39362103-88181983-0CFC-46AA-BFD4-B9910B457D69Q39455504-FD90D59B-0CF8-4840-A5E4-070DD58DD13AQ39532016-DC8DFACD-7BFC-4C8B-91FA-E79191491211Q39995934-546996C0-6127-4CD6-A1E1-7D4440B5A885Q42930682-3B70B692-7F73-401B-9309-AE5059C905D6Q43741328-71DFB016-5843-463F-B368-42AF5FD59F14Q47606949-784E25F6-8612-4196-A077-3208F050F0D8Q54457164-8FF6BD0F-D32D-4427-A48E-E91BCAF10DE5Q56604037-D87C3D36-3989-4054-9151-A529347E3136Q56915799-D6EA61E7-F2AB-4863-9EA5-9226B5267956Q57001160-7DDDCC6A-55D2-4EAD-B82A-973C192832F5Q57001166-2A1FADC2-95CE-410A-817D-DE1E985A532AQ89747982-C6446C77-F249-4B95-A98B-80784BFA386FQ91506468-CB5A4608-18DA-4A0D-AF49-73229FDADF39Q91525890-8013B725-1731-4A14-8F3C-733E85E430F1Q91717195-E2ECA3AB-C395-4769-9938-3678AD12CA15
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Bissan Al-Lazikani
@ast
Bissan Al-Lazikani
@en
Bissan Al-Lazikani
@es
Bissan Al-Lazikani
@nl
Bissan Al-Lazikani
@sl
type
label
Bissan Al-Lazikani
@ast
Bissan Al-Lazikani
@en
Bissan Al-Lazikani
@es
Bissan Al-Lazikani
@nl
Bissan Al-Lazikani
@sl
altLabel
Bissan Overington
@en
prefLabel
Bissan Al-Lazikani
@ast
Bissan Al-Lazikani
@en
Bissan Al-Lazikani
@es
Bissan Al-Lazikani
@nl
Bissan Al-Lazikani
@sl
P108
P106
P108
P21
P2456
P31
P496
0000-0003-3367-2519
P569
2000-01-01T00:00:00Z